Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Stephen L. Hauser(University of California, San Francisco), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Ludwig Kappos(University Hospital of Basel), Noemi Pasquarelli(Roche (Switzerland)), Harold Koendgen(Roche (Switzerland)), Cathy Chognot(Roche (Switzerland)), Ashish Pradhan(Royal Preston Hospital), Richard A. Hughes(Biogen (United States)), Kalpesh Prajapati(Roche (Switzerland)), Licínio Craveiro(Roche (Switzerland))
Cited by 181
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k